Posts Tagged ‘GLP-1 agonists’

A new analysis from Milliman has a revelation for health plan managers complaining loudly about the burdensome costs of GLP-1s blowing up their budgets. They’re doing it wrong. Expenses for GLP-1s that can dramatically improve the health of persons with obesity simply do not have to break the bank for a health plan. In fact, […]

“If you don’t have a solution for me, then it’s not a problem.” This concise statement of wisdom distilled from human behavior explains why it has been so hard for so many years to have people pay attention to obesity in any constructive way. Doctors largely ignored it and rarely diagnosed it. Patients denied it. […]

The annual meeting of the American Society of Clinical Oncology is not where we typically get insights on obesity. But from this year’s meeting, another hint emerges that treating obesity treatment may prevent some of the cancer that arises from obesity. This hint comes from a large and seemingly careful study of 170,030 persons with […]

We do not think for a minute that Lilly or Novo Nordisk will be pursuing any sort of mental health indication for semaglutide or tirzepatide. But it increasingly appears that the effect of GLP-1 use for either diabetes or obesity is more positive than negative for mental health. A new systematic review and meta-analysis in […]

The news in obesity research these days is so full of headlines about a multitude of new medicines in development that it is easy to lose count. All too often, these are early stage or even pre-clinical notions of a potential treatment. So yesterday, it was good news indeed to hear that a once-daily oral […]

Nothing succeeds like success. And thus, the success of GLP-1 medicines for obesity seems to be prompting a re-ordering of marketing for packaged food. Under the Healthy Choice brand, ConAgra has begun promoting an ON TRACK badge that identifies their meals as “GLP-1 Friendly,” as well as high in fiber and protein. ConAgra Senior VP […]

Twenty-nine years ago, scientists discovered that GLP-1 agonists, acting in the brain, could regulate feeding behaviors. In a keynote address to the Columbia Cornell Obesity Medicine course yesterday, Richard DiMarchi presented a compelling, detailed description of how this all unfolded. Way back in 1996, DiMarchi and colleagues at Lilly sought a patent for using a […]

Over the last few decades, there have not been a lot of bright spots for metabolic health. But here’s one. A new paper in Diabetes Care tells us diabetes mortality actually dropped between 2000 and 2019. The authors, led by Hasan Nassereldine, suggest that the decline in diabetes deaths could be due to the adoption […]

More than a decade ago, targeting amylin receptors for treating obesity looked like hot opportunity. Amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells, plays a role in regulating satiety and food intake. An amylin analog, pramlintide, gained FDA approval for treating diabetes. But efforts to develop it for treating obesity never quite […]

Early on after semaglutide captured public attention, people started noticing that the drug was not only helping people reduce excessive weight, it seemed to reduce the desire for drinking alcohol. But until now, all we’ve had to support this idea were anecdotes and retrospective observational studies. Yesterday, JAMA Psychiatry published an RCT offering stronger evidence […]